Jade Biosciences Inc Ordinary Shares JBIO 深 滬
等待開盤 10-30 09:30:00 美东时间
9.49
-0.300
-3.06%
華盛通- 最 高10.28
- 今 開9.78
- 成交量 13.94万股
- 最 低 9.36
- 昨 收 9.79
- 總市值 4.36亿
- 52周最高 16.275
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 -5.60
- 委 比 80.53%
- 總股本 4599.49万
- 歷史最高 1050.525
- 量 比 0.93
- 振 幅 9.40%
- 歷史最低 -40.25
- 每 手 1
- 風險率 3.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jade Biosciences To Present New Preclinical Safety, Translational Data For Immunoglobulin A Nephropathy Candidate JADE101 American Society of Nephrology Kidney Week
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing
10-18 04:09
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
Jade Biosciences will present new preclinical safety and translational data for JADE101, its lead investigational candidate for immunoglobulin A nephropathy (IgAN), during two poster sessions at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is a potentially best-in-class disease-modifying anti-APRIL monoclonal antibody designed to selectively inhibit APRIL in patients with IgAN. The therapy is currently being evaluated in a P...
10-17 20:05
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
Jade Biosciences announces PIPE financing of $135M in gross proceeds, Cash Runway Into 2028
Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of (i) 13,368,164 shares of its common stock ("Common Stock") at a purchase price of $9.14 per share and (ii) pre-funded warrants
10-07 19:07
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
Jade Biosciences unveiled JADE201, an investigational half-life extended, afucosylated monoclonal antibody targeting BAFF-R, designed to improve B-cell depletion in autoimmune diseases. With high binding affinity and extended half-life, JADE201 aims to provide deeper, more durable B-cell depletion with less frequent dosing. A first-in-human trial for rheumatoid arthritis is expected to begin in early 2026. JADE201 builds on the clinical validatio...
10-07 11:05
Jade Biosciences’ Chief Medical Officer Departs
Jade Biosciences ( ($JBIO) ) has provided an announcement. On September 9, 2025...
09-09 19:27
Jade Biosciences Starts Phase 1 Trial Of JADE101 Antibody For IgA Nephropathy, Eyes 2026 Data
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has dosed the first
09-02 19:03
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
A clinical-stage biotechnology company, Jade Biosciences, has initiated a Phase 1 trial for JADE101, a monoclonal antibody targeting APRIL for IgAN treatment. JADE101 shows high binding affinity and potential for infrequent dosing. Mid-2026 interim data will guide dose selection based on biomarkers.
09-02 11:00
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $18
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $17 to $18.
08-14 22:02
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jade Biosciences reported financial results for Q2 2025, highlighting $220.9M in cash and plans to advance its lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy. Preclinical data presented at the European Renal Association Congress demonstrated JADE101's potential as a best-in-class therapy, with strong APRIL binding affinity and sustained IgA suppression. A Phase 1 clinical trial in healthy volunteers is expected to b...
08-13 20:05
